Oxidative stress in chronic renal failure

Free Radical Research

Volumn 29, Issue 1, 1998, Pages 1-11

  Hasselwander, Oliver ^a   Young, Ian S ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; AZATHIOPRINE; CYCLOSPORIN; FREE RADICAL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; RECOMBINANT ERYTHROPOIETIN; VERY LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; DYSLIPIDEMIA; GRAFT FAILURE; HUMAN; KIDNEY TRANSPLANTATION; LIPOPROTEIN METABOLISM; MORBIDITY; OXIDATIVE STRESS; REVIEW;

EID: 0031662216     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/10715769800300011     Document Type: Review

References (118)

1. Lindner, A., Charra, B., Sherrard, D. J. and Scribner, B. H. (1974). Accelerated atherosclerosis in prolonged maintenance hemodialysis. New England Journal of Medicine, 290, 697-701.
2. Raine, A. E. G., MacMahon, S. H., Selwood, N. H., Wing, A. J. and Brunner, F. P. (1991). Mortality from myocardial infarction in patients on renal replacement therapy. Nephrology Dialysis Transplantation, 6, 902.
3. Raine, A. E. G., Margreiter, R., Brunner, F. P., Ehrich, J. H. H., Geerlings, W., Landais, P., Loirat, C., Mallick, N. P., Selwood, N. H., Tufveson, G. and Valderrabano, F. (1992). Report on management of renal failure in Europe XXII, 1991. Nephrology Dialysis Transplantation, 7, (Suppl 2), 7-36.
4. Degoulet, P., Legrain, M., Réach, I., Aimé, F., Devriès, C., Rojas, P. and Jakobs, C. (1982). Mortality risk factors in patients treated by hemodialysis. Nephron, 31, 103-110.
5. Wheeler, D. C. (1996). Cardiovascular disease in patients with chronic renal failure. Lancet, 348, 1673-1674.
6. Witztum, J. L. and Steinberg, D. (1991). Role of oxidised low density lipoprotein in atherogenesis. Journal of Clinical Investigation, 88, 1785-1792.
7. Witztum, J. L. (1993). Susceptibility of low density lipoprotein to oxidative modification. American Journal of Medicine, 94, 347-349.
8. Reaven, P. D. and Witztum, J. L. (1995). The role of oxidation of LDL in atherogenesis. Endocrinologist, 5, 44-54.
9. Parthasarathy, S., Wieland, E. and Steinberg, D. (1988). A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proceedings of the National Academy of Sciences USA, 86, 1046-1050.
10. O'Leary, V. J., Darley-Usmar, V. M., Russell, L. J. and Stone, D. (1992). Pro-oxidant effects of lipoxygenase-derived peroxides on the copper-initiated oxidation of low density lipoprotein. Biochemical Journal, 282, 631-634.
11. Smith, C., Mitchinson, M. J., Aruoma, O. I. and Halliwell, B. (1992). Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochemical Journal, 286, 901-905.
12. Heinecke, J. W. (1997). Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Current Opinion in Lipidology, 8, 268-274.
13. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C. and Witztum, J. L. (1989). Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. New England Journal of Medicine, 320, 915-924.
14. Salonen, J. T., Yla-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., Nyyssonen, K., Palinski, W. and Witztum, J. L. (1992). Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 339, 883-887.
15. Bergmark, C., Wu, R., de Faire, U., Lefvert, A. K. and Swedenborg, J. (1995). Patients with early onset peripheral vascular disease have increased levels of autoantibodies against oxidised LDL. Arteriosclerosis Thrombosis and Vascular Biology, 15, 441-445.
16. Peuchant, E., Carbonneau, M.-A., Dubourg, L., Thomas, M. J., Perromat, A. and Clerc, M. (1994). Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radical Biology Medicine, 16, 339-346.
17. Daschner, M., Lenhartz, H., Bötticher, D., Schaefer, F., Wollschläger, M., Mehls, O. and Leichsenring, M. (1996). Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney International, 50, 1268-1272.
18. Witko-Sarsat, V., Friedlander, M., Capeillère-Blandin, C., Nguyen-Khoa, T., Nguyen, A. T., Zingraff, J., Jungers, P. and Descamps-Latscha, B. (1996). Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International, 49, 1304-1313.
19. Roselaar, S. E., Nazhat, N. B., Winyard, P. G., Jone, P., Cunningham, J. and Blake, D. R. (1995). Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney International, 48, 199-206.
20. Maher, E. R., Wickens, D. G., Griffin, J. F. A., Kyle, P., Curtis, J. R. and Dormandy, T. L. (1988). Neutropenia and plasma free radical products during haemodialysis. Nephrology Dialysis Transplantation, 3, 277-283.
21. Schmidtmann, S., Baehr, R. and Precht, K. (1990). Free radicals induce increased lysis of red blood cells after haemodialysis. Nephrology Dialysis Transplantation, 5, 600-603.
22. Descamps-Latscha, B., Goldfarb, B. and Nguyen, A. T. (1991). Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study. Nephron, 59, 279-285.
23. Nguyen, A. T., Lethias, C., Zingraff, J., Herbelin, A., Naret, C. and Descamps-Latscha, B. (1985). Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney International, 28, 158-167.
24. Himmelfarb, J., Ault, K. A., Holbrook, D., Leeberand, D. A. and Hakim, R. M. (1993). Intradialytic granulocyte reactive oxygen species production: A prospective, crossover trial. Journal of the American Society of Nephrology, 4, 178-186.
25. Harlan, J. M., Killen, P. D., Harker, L. A., Striker, G. E. and Wright, D. G. (1981). Neutrophil-mediated endothelial injury in vitro. Journal of Clinical Investigation, 68, 1394-1403.
26. Weiss, S. J. (1989). Tissue destruction by neutrophils. New England Journal of Medicine, 320, 365-376.
27. Lyons, T. J. (1991). Oxidised low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Medicine, 8, 411-419.
28. Wolff, S. P., Jiang, Z. Y. and Hunt, J. V. (1991). Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radical Biology and Medicine, 10, 339-352.
29. Gugliucci, A. and Bendayan, M. (1996). Renal fate of circulating advanced glycated end-products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabelologia, 39, 149-160.
30. Ranjadayalan, K., Umachandran, V., Davies, S. W., Syndercombe-Court, D., Gutteridge, C. N. and Timmis, A. D. (1991). Thrombolytic treatment in acute myocardial infarction: neutrophil activation, peripheral leukocyte responses, and myocardial injury. British Heart Journal, 66, 10-14.
31. Pronai, L., Hiramatsu, K., Saigusa, Y. and Nakazawa, H. (1991). Low superoxide scavenging activity associated with enhanced superoxide generation by monocytes from male hypertriglyceridaemia patients with and without diabetes. Atherosclerosis, 90, 9-47.
32. Sunder-Plassmann, G. and Hörl, W. H. (1997). Erythropoietin and iron. Clinical Nephrology, 47, 141-157.
33. Aust, S. D., Morehouse, L. A. and Thomas, C. E. (1985). The role of transition metals in oxygen radical reactions. Journal of Free Radical Biology and Medicine, 1, 3-25.
34. van Lenten, B. J., Prieve, J., Navab, M., Hama, S., Lusis, A. J. and Fogelman, A. M. (1995). Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. Journal of Clinical Investigation, 95, 2104-2110.
35. Delmas-Beauvieux, M.-C., Combe, C., Peuchant, E., Carbonneau, M.-A., Dubourg, L., de Précigout, V., Aparicio, M. and Clerc, M. (1995). Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron. Nephron, 69, 404-410.
36. Esterbauer, H., Gebicki, J., Puhl, H. and Jürgens, G. (1992). The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine, 13, 341-390.
37. Riemersma, R. A., Wood, D. A., Macintyre, C. C. A., Elton, R. A., Gey, K. F. and Oliver, M. F. (1991). Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet, 337, 1-5.
38. Gey, K. G., Puska, P., Jordan, P. and Moser, U. K. (1991). Inverse correlation between vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. American Journal of Clinical Nutrition, 53, (Suppl), 326-334.
39. Van den Berg, J. J. M., Kuypers, F. A., Roelofsen, B. and Op den Kamp, J. A. F. (1990). The cooperative action of vitamins E and C in the protection against peroxidation of parinaric acid in human erythrocyte membranes. Chemistry and Physics of Lipids, 53, 309-320.
40. Loughrey, C. M., Young, I. S., Lightbody, J. H., McMaster, D., McNamee, P. T. and Trimble, E. R. (1994). Oxidative stress in hemodialysis. Quarterly Journal of Medicine, 87, 679-683.
41. Jackson, P., Loughrey, C. M., Lightbody, J. H., McNamee, P. T. and Young, I. S. (1995). Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic-renal-failure. Clinical Chemistry, 41, 1135-1138.
42. Ha, T. K. K., Sattar, N., Talwar, D., Cooney, J., Simpson, K., O'Reilly, D. S. J. and Lean, M. E. J. (1996). Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. Quarterly Journal of Medicine, 89, 765-769.
43. Kopple, J. D. and Swendseid, M. E. (1975). Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney International, 7, 579-584.
44. Zarling, E. J. and Gottlieb, K. (1994). Nutrition aspects of continuous ambulatory peritoneal dialysis. A review. Journal of the American College of Nutrition, 13, 133-138.
45. Peuchant, E., Delmas-Beauvieux, M.-C., Dubourg, L., Thomas, M.-J., Perromat, A., Aparicio, M., Clerc, M. and Combe, C. (1997). Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radical Biology and Medicine, 22, 313-320.
46. Wilke, B. C., Vidailhet, M., Favier, A., Guillemin, C., Ducros, V., Arnaud, J. and Richard, M. J. (1992). Selenium, glutathione peroxidase (GSH-PX), and lipid-peroxidation products before and after selenium supplementation. Clinica Chimica Acta, 207, 137-142.
47. Girelli, D., Olivieri, O., Stanzial, A. M., Azzini, M., Lupo, A., Bernich, P., Menini, C., Gammaro, L. and Corrocher, R. (1993). Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: Relations to dialysis treatments, diet and cardiovascular complications. Clinical Science, 84, 611-617.
48. Ceballos-Picot, I., Witko-Sarsat, V., Merad-Boudia, M., Nguyen, A. T., Thévenin, M., Jaudon, M. C., Zingraff, J., Verger, C., Jungers, P. and Descamps-Latscha, B. (1996). Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biology and Medicine, 21, 845-853.
49. Yoshimura, S., Suemizu, H., Nomoto, Y., Sakai, H., Katsuoka, Y., Kawamura, N. and Moriuchi, T. (1996). Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron, 73, 207-211.
50. Bonomini, M., Forster, S., Manfrini, V., de Risio, F., Steiner, M., Vidovich, M. I., Klinkmann, H., Ivanovich, P. and Albertazzi (1996). Geographic factors and plasma selenium in uremia and dialysis. Nephron, 72, 197-204.
51. Roxborough, H. E. and Young, I. S. (1995). Carbamylation of proteins and atherogenesis in renal failure. Medical Hypotheses, 45, 125-128.
52. Stim, J., Shaykh, M., Anwar, F., Ansari, A., Arruda, J. A. L. and Dunea, G. (1995). Factors determining hemoglobin carbamylation in renal failure. Kidney International, 48, 1605-1610.
53. Dengler, T. J., Robertz-Vaupel, G. M. and Dengler, H. J. (1992), Albumin binding in uremia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. European Journal of Clinical Pharmacology, 43, 491-499.
54. Roxborough, H. E., Millar, C. A., McEneny, J. and Young, I. S. (1995). Carbamylation inhibits the ferroxidase activity of ceruloplasmin. Biochemical and Biophysical Research Communications, 214, 1073-1078.
55. Arai, K., Iizuka, S., Tada, Y., Oikawa, K. and Taniguchi, N. (1987). Increase in the glucosylated form of erythrocyte Cu-Zn superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity. Biochimica Biophysica Acta, 924, 292-296.
56. Miyata, T., Wada, Y., Cai, Z., Iida, Y., Horie, K., Yasuda, Y., Maeda, K., Kurokawa, K. and van Ypersele de Strihou, C. (1997). Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney International, 51, 1170-1181.
57. Winyard, P. G., Hider, R. C., Brailsford, S., Drake, A. F., Lunec, J. and Blake, D. R. (1989). Effects of oxidative stress on some physicochemical properties of ceruloplasmin. Biochemical Journal, 258, 435-445.
58. Chan, M. K., Varghese, Z. and Moorhead, J. F. (1981). Lipid abnormalities in uremia, dialysis and transplantation. Kidney International, 19, 625-637.
59. Joven, J., Vilella, E., Ahmad, S., Cheung, M. C. and Brunzell, J. D. (1993). Lipoprotein heterogeneity in end-stage renal-disease. Kidney International, 43, 410-418.
60. Attman, P.-O., Samuelsson, O. and Alaupovic, P. (1993). Lipoprotein metabolism and renal failure. American Journal of Kidney Diseases, 21, 573-592.
61. Appel, G. (1991). Lipid abnormalities in renal disease. Kidney International, 39, 169-183.
62. Short, C. D. and Durrington, P. N. (1990). Hyperlipidaemia and renal disease. Ballière's Clinical Endocrinology and Metabolism, 4, 777-806.
63. Loughrey, C. M., Young, I. S., McEneny, J., McDowell, I. F. W., McMaster, C., McNamee, P. T. and Trimble, E. R. (1994). Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis, 110, 185-193.
64. Sutherland, W. H. F., Walker, R. J., Ball, M. J., Stapley, S. A. and Robertson, M. C. (1995). Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney International, 48, 227-236.
65. Schulz, T., Schiffl, H., Scheithe, R., Hrboticky, N. and Lorenz, R. (1995). Preserved antioxidative defence of lipoproteins in renal failure and during hemodialysis. American Journal of Kidney Diseases, 25, 564-571.
66. Westhuyzen, J., Saltissi, D. and Healy, H. (1997). Oxidation of low density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls. Atherosclerosis, 129, 199-205.
67. Parthasarathy, S., Khoo, J. C., Miller, E., Barnett, J., Witztum, J. L. and Steinberg, D. (1990). Low density lipoprotein rich in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. Proceedings of the National Academy of Sciences USA, 87, 3894-3898.
68. Horkko, S., Huttunen, K. and Kesaniemi, Y. A. (1995). Decreased clearance of low density lipoprotein in uremic patients under dialysis treatment. Kidney International, 47, 1732-1740.
69. Liu, M., Krul, E. S. and Subbaiah, P. V. (1992). Effect of apoprotein b conformation on the activation of lysolecithin acyltransferase and lecithin-cholesterol acyltransferase - studies with subfractions of low density lipoproteins. Journal of Biological Chemistry, 267, 5139-5147.
70. Horkko, S., Savolainen, M. J., Kervinen, K. and Kesaniemi, Y. A. (1992). Carbamylation-induced alterations in low density lipoprotein metabolism. Kidney International, 41, 1175-1181.
71. Horkko, S., Huttenen, K., Kervinen, K. and Kesaniemi, Y. A. (1994). Decreased clearance of uremic and mildly carbamylated low density lipoprotein. European Journal of Clinical Investigation, 24, 105-113.
72. Maggi, E., Bellazzi, R., Gazo, A., Seccia, M. and Bellomo, G. (1994). Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney International, 46, 869-876.
73. Armstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H. and Seidel, D. (1986). The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis, 62, 249-257.
74. Scanu, A. M. and Fless, G. M. (1990). Lipoprotein (a) and biological relevance. Journal of Clinical Investigation, 85, 1709-1715.
75. Parra, H. J., Mezdour, H., Cachera, C., Dracon, M., Tacquet, A. and Fruchart, J. C. (1987). Lp(a) lipoprotein in patients with chronic renal failure treated with hemodialysis. Clinical Chemistry, 33, 721.
76. Kronenburg, F., Konig, P., Neyer, U., Auinger, M., Pribasnig, A., Lang, U., Reitinger, J., Pinter, G., Utermann, G. and Dieplinger, H. (1994). Multicenter study of lipoprotein (a) and apolipoprotein (a) pheno-types in patients with end-stage renal disease treated with haemodialysis or continuous ambulatory peritoneal dialysis, Journal of the American Society of Nephrohgy, 6, 110-120.
77. Cressman, M. D., Heyka, R. J., Paganini, E. P., O'Neil, J., Skibinski, C. I. and Hoff, H. F. (1992). Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation, 86, 475-482.
78. Norbeck, H. E. and Carlson, L. A. (1980). Increased frequency of late pre-β lipoproteins (LPβ) in isolated serum very low density lipoproteins in uremia. European Journal of Clinical Investigation, 10, 423-426.
79. Zacchello, G., Pagnan, A., Sidran, M. P., Ziron, L., Braggion, M., Pavanello, L. and Facchin, P. (1987). Further definition of lipid-lipoprotein abnormalities in children with various degrees of chronic renal insufficiency. Pediatric Research, 21, 462-465.
80. Mahley, R. W., Innerarity, T. L., Brown, M. S., Ho, Y. K. and Goldstein, J. L. (1980). Chlesterol ester synthesis in macrophages: stimulation by β-very low density lipoproteins from cholesterol-fed rabbits of several species. Journal of Lipid Research, 21, 970-980.
81. Parthasarathy, S., Quinn, M. T., Schwenke, D. C., Carew, T. E. and Steinberg, D. (1989). Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis, 9, 398-404.
82. Horrigan, S., Campbell, J. H. and Campbell, G. R. (1991). Oxidation of β-very low density lipoprotein by endothelial cells enhances its metabolism by smooth muscle cells in culture. Arteriosclerosis and Thrombosis, 11, 279-289.
83. McEneny, J., Loughrey, C. M., McNamee, P. T., Trimble, E. R. and Young, I. S. (1997). Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis, 129, 215-220.
84. Skinner, E. R. and Wilson, H. M. (1990). High density lipoprotein subfractions and cardiovascular disease. Biochemical Society Transactions, 18, 1074-1076.
85. Hahn, R., Oette, K., Mondorf, H., Finke, K. and Sieberth, H. G. (1983). Analysis of cardiovascular risk factors in chronic-hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis, 48, 279-288.
86. Hessler, J. R., Robertson, A. L. Jr. and Chisolm, G. M. (1979). LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis, 32, 213-229.
87. Klimov, A. N., Nikiforova, A. A., Pleskov, V. M., Kuzmin, A. A., Kalashnikova, N. N. and Antipova, T. O. (1989). The protective action of high density lipoproteins, their subfractions, and lecithin-cholesterol acetyltransferase in the peroxide modification of low density lipoproteins. Biochemistry USSR, 54, 93-97.
88. Parthasarathy, S., Barnett, J. and Fong, L. G. (1990). High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochimica and Biophysica Acta, 1044, 275-283.
89. Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., Laks, H. and Fogelman, A. M. (1991). Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. Journal of Clinical Investigation, 88, 2039-2046.
90. Mackness, M. I., Arrol, S., Abbott, C. and Durrington, P. N. (1993). Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis, 104, 129-135.
91. Stafforini, D. M., Zimmerman, G. A., McIntyre, T. M. and Prescott, S. M. (1992). The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Transactions of the Association of American Physicians, 105, 44-63.
92. Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M. and Navab, M. (1995). Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Journal of Clinical Investigation, 96, 2882-2891.
93. Watson, A. D., Navab, M., Hama, A. Y., Sevanian, A., Prescott, S. M., Stafforini, D. M., McIntyre, T. M., La Du, B. N., Fogelman, A. M. and Berliner, J. A. (1995). Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. Journal of Clinical Investigation, 95, 774-782.
94. Adkins, S., Gan, K. N., Mody, M. and La Du, B. N. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. American Journal of Human Genetics, 52, 598-608.
95. Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J. and Furlong, C. E. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3, 73-76.
96. Blatter-Garin, M.-C., James, R. W., Dussoix, P., Blanché, H., Passa, P. and Froguel, P. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation, 99, 62-66.
97. Ruiz, J., Blanché, H., James, R. W., Garin, M.-C., Vaisse, C., Charpentier, G., Cohen, N., Morabia, A., Passa, P. and Froguel, P. (1995). Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet, 346, 869-872.
98. Schiavon, R., De Fanti, E., Giavarina, D., Biasioli, S., Cavalcanti, G. and Guidi, G. (1996). Serum paraoxonase activity is decreased in uremic patients. Clinica Chimica Acta, 247, 71-80.
99. Hasselwander, O., McMaster, D., Fogarty, D. G., Maxwell, A. P., Nicholls, D. P. and Young, I. S. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clinical Chemistry, in press.
100. Finkenstein, J. D. (1990). Methionine metabolism in mammals. Journal of Nutritional Biochemistry, 1, 228-237.
101. Malinov, M. R., Kang, S. S., Taylor, L. M., Wong, P. W. K., Coull, B., Inahara, T., Mukerjee, D., Sexton, G. and Upson, B. (1989). Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation, 79, 1180-1186.
102. Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B. and Graham, I. (1991). Hyperhomocysteinemia, an independent risk factor for vascular disease. New England Journal of Medicine, 324, 1149-1155.
103. Stampfer, M. J., Malinov, M. R., Willet, W. C., Newcomer, L. M., Upson, B., Ullmann, D., Tishler, P. V. and Hennekens, C. H. (1992). A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. Journal of the American Medical Association, 268, 877-881.
104. Parthasarathy, S. (1987). Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochimica Biophysica Acta, 917, 337-340.
105. Heinecke, J. W., Rosen, H., Suzuki, L. A. and Chait, A. (1987). The role of sulphur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. Journal of Biological Chemistry, 262, 10098-10103.
106. Blom, H. J., Kleinveld, H. A., Boers, G. H. J., Demacker, P. N. M., Haklemmers, H. L. M., Poelepothoff, M. T. W. B. T. and Trijbels, J. M. F. (1995). Lipid peroxidation and susceptibility of low density lipoprotein to in vitro oxidation in hyperhomocysteinemia. European Journal of Clinical Investigation, 25, 149-154.
107. Wilcken, D. E. L. and Gupta, V. J. (1979). Sulphur-containing amino acids in chronic renal failure with preference to homocysteine and cysteine-homocysteine mixed disulphide. European Journal of Clinical Investigation, 9, 301-307.
108. Chauveau, P., Chadefaux, B., Coudé, M., Aupetit, J., Hannedouche, T., Kamoun, P. and Jungers, P. (1993). Hyperhomocysteinaemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney International, 43, (Suppl 41), S72-S77.
109. Wilcken, D. E. L., Gupta, V. J. and Betts, A. K. (1981). Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clinical Science, 61, 743-749.
110. Adeva Andany, M. (1995). Is atherosclerosis equivalent to cholesterol? Nephron, 71, 487-488.
111. Wilcken, D. E. L., Dudman, N. P. B., Tyrrell, P. A. and Robertson, M. R. (1988). Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism, 37, 697-701.
112. Janssen, M. J. F. M., van Guldener, C., de Jong, G. M., van den Berg, M., Stehouver, C. D. A. and Donker, A. J. M. (1996). Folic acid treatment of hyperhomocysteinemia in dialysis patients. Mineral Electrolyte Metabolism, 22, 110-114.
113. European Multicenter Trial Group (1987). Cyclosporine in cadaveric renal transplantation: 5 year follow-up of a multicenter trial. Lancet, 2, 506-507.
114. Raine, A. E. G., Carter, R., Mann, J. I. and Morris, P. J. (1988). Adverse effect of cyclosporine on plasma cholesterol in renal transplant recipients. Nephrology Dialysis Transplantation, 3, 458-463.
115. Chapman, J. R., Marcen, R., Ariaz, M. and Raine, A. E. G. (1987). Hypertension after renal transplantation: A comparison of cyclosporine and conventional immunosuppression. Transplantation, 43, 860-864.
116. Braun, W. E. (1990). Long-term complications of renal transplantation. Kidney International, 37, 1363-1378.
117. Apanay, D. C., Neylan, J. F., Ragab, M. S. and Sgoutas, D. S. (1994). Cyslosporine increases the oxidizability of low density lipoproteins in renal transplant recipients. Transplantation, 58, 663-669.
118. van den Dorpel, M. A., Ghanem, H., Rischen-Vos, J., Man in't Veld, A. J., Jansen, H. and Weimar, W. (1997). Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney International, 51, 1608-1612.